Development of new formulation of inosine acedoben dimepranol powder for oral solution in sachets
DOI:
https://doi.org/10.2478/amb-2024-0039Keywords:
Inosine Acedoben Dimepranol (IAD), powder for oral solution in sachetsAbstract
Inosine Acedoben Dimepranol (IAD) has immunomodulatory and antiviral properties and is used in the treatment of viral infections. The aim of the present study was to develop a powder for oral solution in sachets containing high dose IAD (1000 mg). The
formulations were prepared by direct dry mixing of the components using the dilution principle. Optimal composition and process parameters for the development of high dosage powder were established. Solubility studies showed pH-dependent solubility of IAD. The prepared powder was characterized by a short reconstitution time. In addition, the oral solution exhibits good organoleptic properties and remains stable for 30 min. Stability studies indicated that the sachets remained stable under accelerated conditions for 3 months. In conclusion, the developed powder for oral solution in sachets containing 1000 mg IAD represents an economical alternative to other solid dosage forms with the advantages of rapid dissolution and convenient intake for the patient.
References
Kovachev SM. A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients. Infect Drug Resist. 2021, 14:2039-2049. doi: 10.2147/IDR.S296709
Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther. 2019, 36(8):1878-1905. doi: 10.1007/s12325-019-00995-6999
Beran J, Špajdel M, Slíva J. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease. Viruses. 2021, 13:2246. doi.org/10.3390/v13112246
Jayanthi CR, Swain AK, Ganga RT, et al. Effcacy and Safety of Inosine Pranobex in COVID-19 Patients: A Multicenter Phase 3 Randomized Double-Blind, Placebo-Controlled Trial. Adv Ther (Weinh). 2022, 2200159. doi: 10.1002/adtp.202200159
Chen M, Zhang Y, Que XT, et al. Pharmacokinetic study of inosiplex tablets in healthy Chinese volunteers by hyphenated HPLC and tandem MS techniques. J Pharm Anal. 2013, 3(6):387-393. doi: 10.1016/j.jpha.2013.03.001.
Gordon P, inventor, Newport Pharmaceuticals, Inc., assignee. Inosine derivatives. United States patent US, 1974, 3857940
Perrie Y, Badhan RK, Kirby DJ, et al. The impact of ageing on the barriers to drug delivery. J Control Release. 2012, 161(2):389-98. doi: 10.1016/j.jconrel.2012.01.020.
European Medicines Agency (2023a) List of nationally authorized medicinal products, Active substance: inosine dimepranol acedoben. EMA/179176/2019. Available from: https://www.ema.europa.eu/sites/default/files/Medicines_output_periodic_safety_update_report_single_assessments.xlsx Accessed 9 Jul 2023.
European Pharmacopoeia (Ph. Eur.) 10th ed. European Directorate for the Quality of Medicines & HealthCare. 2019, Available from: https://www.edqm.eu/en/. Accessed 9 Jul 2023.10. Lahane SH. Optimization of roll compactor variables and formulation of anti-retroviral tablet by roll compaction method. Int J Pharm Sci. 2020, 12(1): 48-53.
European Medicines Agency (2023b) Stability testing of new drug substances and products. CPMP/ICH/2736/99. Available from: https://www.ema.europa.eu/en/ich-q1a-r2-stabilitytesting-new-drug-substances-drug-products-scientific-guideline. Accessed 11 Jul 2023.
Kafedjiiski K. Formulation and in vitro evaluation of inosine acedoben dimepranol tablets. Pharmacia, 2022, 69(2): 319-325. doi: 10.3897/pharmacia.69.e81442.
European Medicines Agency (2010) Guideline on the investigation of bioequivalence. Doc. Ref.: CPMP/EWP/QWP/1401/98
Rev. 1/Corr**. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 11 Jul 2023.
Saharan VA, Kukkar V, Kataria M, et al. Ordered mixing: mechanism, process and applications in pharmaceutical formulations. Asian Journal of Pharmaceutical Sciences. 2008, 3(6): 240-259.
Saint-Lorant G, Leterme P, Gayot A, Flament MP. Influence of carrier on the performance of dry powder inhalers. International Journal of Pharmaceutics. 2007, 334:85-91. doi: 10.1016/j.ijpharm.2006.10.028.
Alen LV, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems, 2001, 9th ed. Baltimore.
Al-Zoubi N, Gharaibeh S, Aljaberi A, Nikolakakis I. Spray Drying for Direct Compression of Pharmaceuticals. Processes. 2021, 9(2): 267. doi: 10.3390/pr9020267.
Kaye BH. Mixing of Powders. In: Fayed ME, Otten L, editors. Handbook of Powder Science & Technology. Springer New
York, NY. 1997, pp. 568-585. doi: 10.1007/978-1-4615-6373-0.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 K. Kafedjiiski, V. Belcheva, M. Radeva-Ilieva, E. Grigorov (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
